Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.
AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...
AstraZeneca's BTK inhibitor Calquence is the first drug in the class to be approved in the US for first-line treatment of mantle cell lymphoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback